Amylyx Pharmaceuticals Inc
AMLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.41B
Close$
$2.33
91.4% downside
Current Fair Value
91.4% downsideOvervalued by 91.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.41 Billion |
|---|---|
| Enterprise Value | $3.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.53 |
| Beta | -0.21 |
| Outstanding Shares | 111,196,883 |
Return
| Return on Equity | -63.59% |
|---|---|
| Return on Assets | -57.49% |
| Return on Invested Capital | -63.38% |
Valuation & Multiples
| P/E Ratio | -19.29 |
|---|---|
| PEG | -403.77 |
| Price to Sales | - |
| Price to Book Ratio | 13.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -21.84 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$59,429
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 29.44% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 104.60% |
|---|---|
| Total Invested | $2.02M▼ 99.90% |
| Investors Holding | 12▼ 211.00% |
ESG Score
No data